Literature DB >> 9751464

Correlation of serum IgA rheumatoid factor levels with disease severity in rheumatoid arthritis.

S Päi1, L Päi, R Birkenfeldt.   

Abstract

In the present study, the IgA rheumatoid factor (IgA RF) was assayed by ELISA in 114 sera of patients with active RA. IgA RF was found in the sera of 38 (33.3%) patients. A total of 56 disease variables were studied, differences in variables between IgA RF positive and negative patients were analyzed. The presence of IgA RF was found to be associated with a rapid progressive course, RA activity, onset of extra-articular manifestations (especially systemic rheumatoid vasculitis), high IgM RF titres, circulating immune complexes, cryoglobulins, and C-reactive protein levels. There was no statistically significant difference in serum IgA levels between IgA RF seropositive and seronegative patients. The presence of IgA RF showed a positive correlation with the level of IgM RF. The results of this study showed that the determination of IgA RF has a practical use in the establishment of the severe course of RA with systemic damages.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9751464     DOI: 10.1080/030097498442352

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  13 in total

Review 1.  To B or not to B the conductor of rheumatoid arthritis orchestra.

Authors:  Rita A Moura; Luis Graca; João E Fonseca
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

2.  Extra-articular manifestations of seronegative and seropositive rheumatoid arthritis.

Authors:  Vjollca Sahatciu-Meka; Sylejman Rexhepi; Suzana Manxhuka-Kerliu; Mjellma Rexhepi
Journal:  Bosn J Basic Med Sci       Date:  2010-02       Impact factor: 3.363

Review 3.  Update on autoantibodies in rheumatoid arthritis.

Authors:  S Louis Bridges
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

4.  Rheumatoid factor measured by fluoroimmunoassay: a responsive measure of rheumatoid arthritis disease activity that is associated with joint damage.

Authors:  E Knijff-Dutmer; W Drossaers-Bakker; A Verhoeven; G van der Sluijs Veer; M Boers; S van der Linden; M van de Laar
Journal:  Ann Rheum Dis       Date:  2002-07       Impact factor: 19.103

5.  Improved rheumatoid digital vasculitis in a patient treated with TNFalpha agent blocking (infliximab).

Authors:  Maurizio Benucci; Francesca Li Gobbi; Gianantonio Saviola; Mariangela Manfredi
Journal:  Rheumatol Int       Date:  2008-05-21       Impact factor: 2.631

6.  Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project).

Authors:  A Kastbom; G Strandberg; A Lindroos; T Skogh
Journal:  Ann Rheum Dis       Date:  2004-09       Impact factor: 19.103

Review 7.  Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value.

Authors:  Martinus A M van Boekel; Erik R Vossenaar; Frank H J van den Hoogen; Walther J van Venrooij
Journal:  Arthritis Res       Date:  2001-11-06

Review 8.  Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis.

Authors:  Filipe Seguro Paula; José Delgado Alves
Journal:  Biologics       Date:  2013-12-09

9.  The association of immunoglobulin A, immunoglobulin G and anti-cyclic citrullinated peptide antibodies with disease activity in seronegative rheumatoid arthritis patients.

Authors:  Mansoor Karimifar; Hamidreza Moussavi; Mehran Babaei; Mojtaba Akbari
Journal:  J Res Med Sci       Date:  2014-09       Impact factor: 1.852

Review 10.  Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies.

Authors:  Y W Song; E H Kang
Journal:  QJM       Date:  2009-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.